{"id":1639,"date":"2026-05-31T16:07:09","date_gmt":"2026-05-31T16:07:09","guid":{"rendered":"https:\/\/bostonrelocationinsider.com\/?p=1639"},"modified":"2026-05-31T16:07:09","modified_gmt":"2026-05-31T16:07:09","slug":"chinas-biotech-ascent-forces-us-industry-to-choose-is-the-country-an-ally-or-an-existential-threat","status":"publish","type":"post","link":"https:\/\/bostonrelocationinsider.com\/?p=1639","title":{"rendered":"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat?"},"content":{"rendered":"<article>\n<div>\n<p><span><i>This story is republished from <\/i><i>STAT<\/i><i>, the health and medicine news site that\u2019s a partner to the Globe. Sign up for STAT\u2019s free Morning Rounds newsletter <\/i><i>here<\/i><i>.<\/i><\/span><\/p>\n<p>Read more <a href=\"https:\/\/bostonrelocationinsider.com\/?p=1637\">The world capital of french fries has a problem: too many potatoes<\/a><\/p>\n<p><span>There\u2019s a schism in America\u2019s drug business, playing out in punchy direct messages, feisty group chats, and the occasional heated in-person exchange.<\/span><\/p>\n<p><span>The problem is China. Fledgling startups and pharmaceutical giants alike are addicted to Chinese drugs, filling their pipelines with would-be blockbusters developed at enviable speed and bought on the cheap. They\u2019ve spent some $60 billion on Chinese molecules in the first three months of 2026 alone, according to state figures. That\u2019s on pace to double last year\u2019s total, which was already 10 times larger than the one from 2021.<\/span><\/p>\n<\/div>\n<div>\n<p><span>No one disagrees that it\u2019s good business. And more drugs moving swiftly through development means hope for patients around the world desperately awaiting new medicines.<\/span><\/p>\n<div>\n<div>\n<div><span>Get Starting Point<\/span><\/div>\n<div><span>A guide through the most important stories of the morning, delivered Monday through Friday.<\/span><\/div>\n<div>\n<div><label>Enter Email<\/label><\/p>\n<div><button>Sign Up<\/button><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p><span>But, according to more than a dozen interviews with industry executives and investors, the question of whether to partner with Chinese firms \u2014 or see them as rivals \u2014 is tearing biotech apart, pitting peers and partners against one another and souring relationships in an otherwise close-knit corporate community. <\/span><\/p>\n<p><span>On one side are biotech loyalists who believe pharmaceutical giants and A-list venture capitalists are frittering away a jewel of American industry by bolstering Chinese companies, threatening the very existence of a trillion-dollar sector. They point to rare earths and electric cars, sectors where China was happy to handle low-cost dirty work for Western incumbents until it built up enough domestic expertise to dominate those markets on its own. Why would drugs be different \u2014 and what happens when the next cancer breakthrough comes from the labs of a state-owned Chinese biotech company?<\/span><\/p>\n<p><span>\u201cThey get you dependent on something and then they use it as leverage,\u201d said the chief executive officer of a U.S. biotech company. \u201cThey\u2019re the coke dealers of globalism.\u201d<\/span><\/p>\n<p><span>On the other side are committed drug developers who see China\u2019s rapid rise as an evolution rather than an existential threat \u2014 and who don\u2019t particularly appreciate accusations of corporate treason. To them the doomsayers sound like dinosaurs in the making, crying Cold War because they can\u2019t compete on the merits.<\/span><\/p>\n<p><span>\u201cThe uncomfortable reality is when these things happen, there are winners and losers,\u201d said one investor who has built startups around Chinese-invented drugs. \u201cThat\u2019s table stakes for full-contact American capitalism.\u201d<\/span><\/p>\n<p><span>There is also a middle group, made up of a small number of investors who believe the emergence of Chinese biotech has created a prisoner\u2019s dilemma: It\u2019d be fine if everyone spurned engagement with Chinese firms, but so long as your rivals are shopping in Shanghai, you\u2019d be foolish to put yourself at a disadvantage. These investors want the government to step in and block future Chinese drug deals.<\/span><\/p>\n<p><span>\u201cUntil I\u2019m not allowed to do it, of course I\u2019m going to do it,\u201d one biotech investor said. \u201cThere are too many for-profit actors in this setting who are willing to launder their ethics to make $100 million on each deal.\u201d<\/span><\/p>\n<p><span>What all three factions have in common is an aversion to speaking out. Most of the investors and entrepreneurs who spoke to STAT did so on the condition of anonymity out of fear that their unadulterated views on the China situation would put them in line for reprisal \u2014 from Chinese partners, well-heeled VCs, pharmaceutical powerbrokers, or a Trump administration with a track record of punishing individual firms.<\/span><\/p>\n<p><span>There\u2019s one executive more than comfortable shouting into that vacuum. Jason Kelly, the 45-year-old CEO of Ginkgo Bioworks, has spent the past few months making the case \u2014 on podcasts, to the fleece-vested viewers of TBPN, and in front-facing videos posted to his X account \u2014 that biotech\u2019s China situation is dangerously untenable. Like Paul Revere in a lab coat, Kelly argues the U.S. needs to slam the door on Chinese licensing deals, speed up the process for domestic clinical trials, and radically reform the American scientific method to compete with lower-cost laboratory labor overseas.<\/span><\/p>\n<p><span>What Kelly is selling, in the literal sense, is a solution to that final demand. Ginkgo, at its Boston headquarters, has constructed an automated lab in which interconnected robots perform the scientific grunt work that underpins every major drug discovery, shuttling samples up and down a track like model trains. The goal is to persuade startups and major drugmakers that Ginkgo\u2019s machines, which don\u2019t need sleep or health insurance, can cheaply and reliably replicate the tasks that would otherwise be outsourced.<\/span><\/p>\n<p><span>\u201cThe ugly secret in biotech is that all the startups are moving to China,\u201d Kelly said on a walk through the buzzing shop floor of Ginkgo\u2019s robot-staffed lab, which the company says is the largest in the world. \u201cWe need to embrace autonomy. We can\u2019t compete on hands pipetting with China.\u201d<\/span><\/p>\n<p><span>He is, to some of his peers, a less-than-ideal messenger for the crusade to save American biotech. Ginkgo has had to pivot since its 2008 foundation, as the company\u2019s animating ambitions sounded a lot more plausible when interest rates were zero. Ambitions were narrowed, costs were cut, and a few hundred people were let go. If you bet 10 bucks on Ginkgo when it went public in 2021, you\u2019d be holding a single shiny quarter in 2026. <\/span><\/p>\n<p><span>Kelly is talking his book when he insists automated labs are integral for biotech\u2019s survival: The robots he believes can save American science also happen to be Ginkgo\u2019s best bet to stay in business. <\/span><\/p>\n<p><span>\u201cI think we have to admit that we are paying scientists three times as much in the U.S., and I do not understand how we plan to be competitive,\u201d Kelly said. \u201cSo yes, I\u2019m selling a solution to that problem \u2014 but I do think it\u2019s a real problem.\u201d<\/span><\/p>\n<p><span>Even skeptics of Kelly appreciate what he\u2019s doing. Robots or otherwise, no one else in the industry is publicly pressuring the U.S. to block investments in Chinese biotech. As one investor put it, \u201cMy belief is our entire industry is dead in 10 years if things don\u2019t change, so why not?\u201d<\/span><\/p>\n<div>\n<div>\n<h3>\u2018Not a random, overnight change\u2019<\/h3>\n<\/div>\n<\/div>\n<p><span>Once you start looking for China\u2019s fingerprints on the American drug industry, you can\u2019t escape them. The biggest IPO in biotech history? Built on Chinese-invented medicines. Buzzy startup launches? Chinese drugs. The latest billion-dollar buyout? Chinese drugs. Pharma\u2019s new arms race in cancer treatment? China, China, and China.<\/span><\/p>\n<p><span>\u201cThis was not a random, overnight change,\u201d said So-Yeon Kang, a Georgetown University professor who has studied China\u2019s ascent. The country spent years deliberately working its way up the pharmaceutical supply chain, she said, first by making chemical raw materials and then by manufacturing medicines, all while learning from the multinational firms happy to take advantage of a bargain. Now, by inventing drugs with Western acquirers in mind, \u201cChina is competing in the supply chain of ideas,\u201d she said.<\/span><\/p>\n<p><span>A decade ago, Chinese-invented molecules accounted for just 8% of the global drug pipeline. As of 2025 that number was north of 40%, according to a recent analysis published in JAMA by Kang and her colleagues. Over that same period, the U.S.\u2019s share of the world\u2019s medicine chest fell from nearly half to less than 35%. By pretty much any metric of biotech productivity \u2014 research spending, patent applications, clinical trials \u2014 China has overtaken the U.S.<\/span><\/p>\n<p><span>The truly cutting-edge stuff remains largely the domain of American labs, Kang said, at least for now. Where Chinese firms have cornered the market is on so-called best-in-class drugs, taking ideas already in the scientific zeitgeist and making them longer-acting, for instance, or more potent. They\u2019re building better mousetraps rather than reinventing pest control.<\/span><\/p>\n<p><span>And American drug hunters, at companies big and small, want in. Venture capitalists and business development teams have been making increasingly frequent pilgrimages to China in recent months, bragging about their close ties in Shanghai and Suzhou, investors said. Analysts at Leerink Partners have dubbed the resulting nexus \u201cthe Wild Wild East.\u201d<\/span><\/p>\n<p><span>Biocom, the trade group representing biotech firms in California, led a squadron of local executives on a trip to China just last month, brokering introductions for companies eager to forge relationships in the country\u2019s burgeoning scene. To Tim Scott, Biocom\u2019s CEO, human disease doesn\u2019t recognize borders, so why shouldn\u2019t international competitors work together once in a while?<\/span><\/p>\n<p><span>\u201cIt\u2019s not a Cold War game of chess; it\u2019s a game of Twister,\u201d Scott said. \u201cWe\u2019re all over each other, and we have to just accept that and make the best of it.\u201d<\/span><\/p>\n<p><span>The math is hard to beat. As one venture capitalist explained, you can spend $10 million on a best-in-class drug from China, or you can hire 25 people in the U.S. and pay them some $40 million over three years to get to the exact same point. In general, going with China works out to a roughly 50% cost savings, he said, meaning the same monetary investment can fund double the work.<\/span><\/p>\n<p>Read more <a href=\"https:\/\/bostonrelocationinsider.com\/?p=1635\">Experimental pill promises new hope for deadly pancreatic cancer<\/a><\/p>\n<p><span>\u201cWe\u2019re going to make half as many medicines if we need twice as much money to make all of them,\u201d he said. \u201cSo is the goal to subsidize the Kendall Square labor ecosystem, or is it to maximize drug productivity?\u201d<\/span><\/p>\n<p><span>That framing misses the point, according to Olivia Kosloff, a senior fellow at American Economic Liberties Project. American biotech companies aren\u2019t competing on price with rival firms in a free market; they\u2019re getting pulverized by a state-sponsored effort to amass geopolitical influence.<\/span><\/p>\n<p><span>\u201cChina is not a neutral global partner,\u201d Kosloff wrote in STAT. \u201cThe Chinese government has pursued an industrial policy of entering an industry at the commodity level, undercutting global prices to attract investment, moving up the value chain, and eventually driving global competitors out of business.\u201d<\/span><\/p>\n<p><span>The endgame isn\u2019t cheaper drugs, one biotech investor said. It\u2019s a future in which cancer drugs are bargaining tools and the U.S.\u2019s access to lifesaving medicines depends on its willingness to kowtow to Beijing.<\/span><\/p>\n<p><span>\u201cWe are seeding a future supply chain crisis,\u201d the investor said. \u201c\u2018Sorry, grandma\u2019s refill\u2019s not going to happen because China took Taiwan.\u2019\u201d <\/span><\/p>\n<div>\n<div>\n<h3>A plan of attack<\/h3>\n<\/div>\n<\/div>\n<p><span>Jason Kelly, self-appointed spokesman for biotech\u2019s Minutemen, has a three-pronged plan to avert biotech disaster. Step one is uncontroversial: The U.S. needs to speed up the process of conducting early-stage trials, an undertaking already in motion at the Food and Drug Administration. Then it needs to invest in making American drug discovery more efficient, embracing new technologies like, say, automated laboratories crafted by Ginkgo Bioworks.<\/span><\/p>\n<p><span>Step three is the divisive one: Kelly wants to forcibly break his industry\u2019s reliance on China.<\/span><\/p>\n<p><span>Under the , enacted last year, American firms can\u2019t invest in certain technologies \u2014 mostly fast drones, faster computers \u2014 tied to China and other \u201ccountries of concern.\u201d The Trump administration could, if it wanted, add biotech to the COINS list of sensitive global industries, effectively banning all this molecular outsourcing. And Kelly believes the U.S. should pull the trigger now, before more American money finds its way into Chinese pockets.<\/span><\/p>\n<p><span>\u201cThis isn\u2019t just about ceding ground on manufacturing,\u201d Kelly said. \u201cIt\u2019s about the frontier. It\u2019s about who owns the future.\u201d<\/span><\/p>\n<p><span>He\u2019s not alone. Earlier this year, seven Republican lawmakers, including Sen. Tom Cotton (R-Ark.), a notable China hawk, sent  to Treasury Secretary Scott Bessent urging him to add biotech to COINS, warning that inaction \u201crisks hollowing out a critical American industry while strengthening that of a foreign adversary.\u201d<\/span><\/p>\n<p><span>The Treasury Department did not respond to requests for comment.<\/span><\/p>\n<p><span>If the administration doesn\u2019t take action, Congress could try. Proponents of the idea said it has broad support among lawmakers and the aides who handle the actual labor of legislation. But getting it over the line might require outflanking the powerful pharmaceutical lobby, they acknowledged.<\/span><\/p>\n<p><span>The Pharmaceutical Research and Manufacturers of America, which spent a record sum on lobbying last year, is not on board with the idea that putting restraints on U.S. drugmakers would slow their Chinese counterparts.<\/span><\/p>\n<p><span>\u201cWe\u2019re not going to regulate ourselves to success here,\u201d said Robert Zirkelbach, PhRMA\u2019s chief public affairs officer. \u201cThe way we win is by making America the most attractive place in the world to invest.\u201d<\/span><\/p>\n<p><span>To some biotech investors, Kelly\u2019s COINS plan simply would deprive American drug developers of promising potential medicines while insulating an industry from the kind of competition it should crave. Instead of crying out for government intervention, biotech should double down on big scientific ideas, investing in areas where the U.S.\u2019s head start on China can be measured in years instead of months. \u201cWe should all put on our big boy pants and try to solve hard problems,\u201d one VC said.<\/span><\/p>\n<p><span>John Crowley, biotech\u2019s man in Washington, is on board with streamlining clinical trials and investing in new technologies. But the CEO of BIO, the trade group representing U.S. biotech companies, sees COINS as an imperfect solution unlikely to solve a very real problem. Capital is stateless, rational, and fluid, Crowley told STAT. If Chinese researchers are doing good science, someone\u2019s going to fund it. <\/span><\/p>\n<p><span>\u201cIt would be a fool\u2019s errand to try to <i>stop<\/i> what\u2019s happening in China,\u201d Crowley said. \u201cLet\u2019s look in the mirror. How do we win in biotech? How do we outcompete China?\u201d<\/span><\/p>\n<div>\n<div>\n<h3>The upside of robots<\/h3>\n<\/div>\n<\/div>\n<p><span>Ginkgo\u2019s robots toil away on the top floor of a retrofitted warehouse in Boston\u2019s Seaport, a building commissioned in 1918 to supply the U.S. Army in World War I. That history is not lost on Kelly, to whom biotech is an integral part of national security, and Boston is its capital.<\/span><\/p>\n<p><span>The local industry is in visible decline. Greater Boston\u2019s laboratory vacancy rates, which were effectively zero as recently as 2023, have soared to nearly 30%, according to  from real estate firm CBRE. Demand has tanked, and much of the available inventory comes in the form of subleases from companies actively downsizing. Biotech jobs in Massachusetts declined year over year for the first time in two decades, per the most recent report from industry group MassBio.<\/span><\/p>\n<p><span>\u201cThat\u2019s really what got me started on being more public about this,\u201d Kelly said. \u201cI\u2019m not going to just sit here and watch Kendall Square melt. We should all be doing something about it.\u201d<\/span><\/p>\n<p><span>One might wonder how building machines that do human jobs could be a net positive for biotech employment. Here, Kelly turns to history again. In the late 1940s, IBM introduced the world\u2019s first mass-produced electronic calculator, promising the nearly one-ton machine could do the work of 150 engineers tethered to their slide rules. Over the ensuing decades, the computational machines got smaller and more powerful \u2014 and the demand for engineering talent exploded in turn. <\/span><\/p>\n<p><span>\u201cThat\u2019s because by automating it, we dramatically increased the return on investment for what was in those engineers\u2019 heads,\u201d he said. The same thing could happen to biotech.<\/span><\/p>\n<p><span>On the sidelines of his automated lab, called Nebula, Kelly reached for a dry-erase board to sketch out Ginkgo\u2019s future. Technologists have historically grappled with the balance between automation and variability, he said. In transportation, the subway is an unbeatable way to automate the trip between two fixed points. But if you want to get each rider to a variable location \u2014 their doorstep, for instance \u2014 your best bet is to put each one behind the wheel of a car. Or at least that was true until Waymo came along, Kelly said, and solved the autonomy-variability problem with a car that drives itself.<\/span><\/p>\n<p><span>Ginkgo aspires to be the Waymo of biotech research. Other companies have figured out how to automate specific laboratory tasks, creating subways of scientific labor. But most experiments still require human hands shuttling liquids back and forth between machines scattered across laboratory benchtops, leading to inefficiencies and traffic jams. Nebula removes the human element, Kelly said, allowing scientists to order up variable experiments and rely on automated lab techs to ferry them home. When running at full steam, the automated lab offers a ten-fold increase in research output per square foot while occupying about one-third the space, according to Ginkgo.<\/span><\/p>\n<p><span>\u201cI don\u2019t see how this isn\u2019t wildly better,\u201d Kelly said.<\/span><\/p>\n<p><span>It had better be. Ginkgo has spent the last two years cutting, pivoting, and offloading parts of its business in an effort to minimize its cash burn and lay eyes on a future in which it makes more money than it spends. The automated lab is the engine of its survival. The short-term sales driver is inviting researchers to order up robot-led experiments from an online menu. The broader vision is to prove Nebula\u2019s value such that the likes of Merck and Pfizer pay Ginkgo to come to their corporate campuses and build bespoke Nebulas for them. <\/span><\/p>\n<p><span>\u201cMy argument is you\u2019re better off building an autonomous lab versus outsourcing your whole operation,\u201d Kelly said. \u201cThe race I\u2019m running is can I prove it before the whole industry moves to China?\u201d<\/span><\/p>\n<p>Read more <a href=\"https:\/\/bostonrelocationinsider.com\/?p=1633\">Game 58: Red Sox at Guardians lineups and notes<\/a><\/p>\n<\/div>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>The question of whether to partner with Chinese firms \u2014 or see them as rivals \u2014 is tearing biotech apart.<\/p>\n","protected":false},"author":1,"featured_media":1638,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9],"tags":[],"class_list":["post-1639","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? - Boston Relocation Insider<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bostonrelocationinsider.com\/?p=1639\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? - Boston Relocation Insider\" \/>\n<meta property=\"og:description\" content=\"The question of whether to partner with Chinese firms \u2014 or see them as rivals \u2014 is tearing biotech apart.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bostonrelocationinsider.com\/?p=1639\" \/>\n<meta property=\"og:site_name\" content=\"Boston Relocation Insider\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-31T16:07:09+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#\\\/schema\\\/person\\\/c08a982d5d5e7124cea9158df226037e\"},\"headline\":\"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat?\",\"datePublished\":\"2026-05-31T16:07:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639\"},\"wordCount\":2940,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/313646086daae7baae5c4476eec26af5.avif\",\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639\",\"url\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639\",\"name\":\"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? - Boston Relocation Insider\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/313646086daae7baae5c4476eec26af5.avif\",\"datePublished\":\"2026-05-31T16:07:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#\\\/schema\\\/person\\\/c08a982d5d5e7124cea9158df226037e\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639#primaryimage\",\"url\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/313646086daae7baae5c4476eec26af5.avif\",\"contentUrl\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/313646086daae7baae5c4476eec26af5.avif\",\"width\":1440,\"height\":958},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?p=1639#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#website\",\"url\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/\",\"name\":\"Boston Relocation Insider\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/#\\\/schema\\\/person\\\/c08a982d5d5e7124cea9158df226037e\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/bostonrelocationinsider.com\"],\"url\":\"https:\\\/\\\/bostonrelocationinsider.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? - Boston Relocation Insider","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bostonrelocationinsider.com\/?p=1639","og_locale":"en_US","og_type":"article","og_title":"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? - Boston Relocation Insider","og_description":"The question of whether to partner with Chinese firms \u2014 or see them as rivals \u2014 is tearing biotech apart.","og_url":"https:\/\/bostonrelocationinsider.com\/?p=1639","og_site_name":"Boston Relocation Insider","article_published_time":"2026-05-31T16:07:09+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bostonrelocationinsider.com\/?p=1639#article","isPartOf":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=1639"},"author":{"name":"admin","@id":"https:\/\/bostonrelocationinsider.com\/#\/schema\/person\/c08a982d5d5e7124cea9158df226037e"},"headline":"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat?","datePublished":"2026-05-31T16:07:09+00:00","mainEntityOfPage":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=1639"},"wordCount":2940,"commentCount":0,"image":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=1639#primaryimage"},"thumbnailUrl":"https:\/\/bostonrelocationinsider.com\/wp-content\/uploads\/2026\/05\/313646086daae7baae5c4476eec26af5.avif","articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/bostonrelocationinsider.com\/?p=1639#respond"]}]},{"@type":"WebPage","@id":"https:\/\/bostonrelocationinsider.com\/?p=1639","url":"https:\/\/bostonrelocationinsider.com\/?p=1639","name":"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat? - Boston Relocation Insider","isPartOf":{"@id":"https:\/\/bostonrelocationinsider.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=1639#primaryimage"},"image":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=1639#primaryimage"},"thumbnailUrl":"https:\/\/bostonrelocationinsider.com\/wp-content\/uploads\/2026\/05\/313646086daae7baae5c4476eec26af5.avif","datePublished":"2026-05-31T16:07:09+00:00","author":{"@id":"https:\/\/bostonrelocationinsider.com\/#\/schema\/person\/c08a982d5d5e7124cea9158df226037e"},"breadcrumb":{"@id":"https:\/\/bostonrelocationinsider.com\/?p=1639#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bostonrelocationinsider.com\/?p=1639"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bostonrelocationinsider.com\/?p=1639#primaryimage","url":"https:\/\/bostonrelocationinsider.com\/wp-content\/uploads\/2026\/05\/313646086daae7baae5c4476eec26af5.avif","contentUrl":"https:\/\/bostonrelocationinsider.com\/wp-content\/uploads\/2026\/05\/313646086daae7baae5c4476eec26af5.avif","width":1440,"height":958},{"@type":"BreadcrumbList","@id":"https:\/\/bostonrelocationinsider.com\/?p=1639#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bostonrelocationinsider.com\/"},{"@type":"ListItem","position":2,"name":"China\u2019s biotech ascent forces US industry to choose: Is the country an ally or an existential threat?"}]},{"@type":"WebSite","@id":"https:\/\/bostonrelocationinsider.com\/#website","url":"https:\/\/bostonrelocationinsider.com\/","name":"Boston Relocation Insider","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bostonrelocationinsider.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bostonrelocationinsider.com\/#\/schema\/person\/c08a982d5d5e7124cea9158df226037e","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/50b1ad2e498f523425ee0a8cc5180a210646db1622662a3d56cc405d3e0c346a?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/bostonrelocationinsider.com"],"url":"https:\/\/bostonrelocationinsider.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/posts\/1639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1639"}],"version-history":[{"count":0,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/posts\/1639\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=\/wp\/v2\/media\/1638"}],"wp:attachment":[{"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bostonrelocationinsider.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}